Literature DB >> 20479324

Acneiform eruption in a patient receiving bevacizumab for glioblastoma multiforme.

Bridget P Keenan, Rachel Abuav.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20479324      PMCID: PMC3895369          DOI: 10.1001/archdermatol.2010.68

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


× No keyword cloud information.
  5 in total

Review 1.  Dermatologic side effects associated with the epidermal growth factor receptor inhibitors.

Authors:  Anna Liza C Agero; Stephen W Dusza; Cristiane Benvenuto-Andrade; Klaus J Busam; Patricia Myskowski; Allan C Halpern
Journal:  J Am Acad Dermatol       Date:  2006-10       Impact factor: 11.527

2.  Skin rash secondary to bevacizumab in a patient with advanced colorectal cancer and relation to response.

Authors:  Vladimir Gotlib; Samer Khaled; Igor Lapko; Nataliya Mar; Muhammad Wasif Saif
Journal:  Anticancer Drugs       Date:  2006-11       Impact factor: 2.248

3.  Papulopustular eruption after intravitreal bevacizumab (Avastin).

Authors:  Luis Amselem; Manuel Diaz-Llopis; Salvador Garcia-Delpech; Javier Montero; Paula Palomares; Enrique Cervera
Journal:  Acta Ophthalmol       Date:  2008-06-18       Impact factor: 3.761

4.  Correlation between rash and a positive drug response associated with bevacizumab in a patient with advanced colorectal cancer.

Authors:  M Wasif Saif; Walter L Longo; Gary Israel
Journal:  Clin Colorectal Cancer       Date:  2008-03       Impact factor: 4.481

5.  Expression and localization of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 in human epidermal appendages: a comparison study by immunofluorescence.

Authors:  X-Y Man; X-H Yang; S-Q Cai; Z-Y Bu; X-J Wu; Z-F Lu; M Zheng
Journal:  Clin Exp Dermatol       Date:  2009-04       Impact factor: 3.470

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.